
Clinical trials
Studies registered on ClinicalTrials.gov, anchored to the NCT number.
42 cards, each checked against its primary source
Search the catalog
Filters
Closeness to humans
Closeness to humans:Any
Order:Newest
Card descriptions are written in Russian for now; English text is coming.
VICTORION-2 PREVENT (inclisiran)
NCT05030428
Hard-outcome test of inclisiran; продолжается.
No news yet
ORION-4 (inclisiran)
NCT03705234
Hard-outcome test of inclisiran; follow-up завершается в 2026, результаты ожидаются в 2027.
No news yet
VICTORION-PLAQUE (inclisiran)
Phase 3NCT05360446
Phase IIIb, 608 randomized, double-blind placebo-controlled.
No news yet
REMBRANDT
Phase 3NCT06305559
Randomized double-blind placebo-controlled; primary endpoint percent change in total noncalcified coronary plaque volume by CCTA at 18 months.
No news yet
BROADWAY (obicetrapib)
Phase 3NCT05142722
Obicetrapib на фоне lipid-lowering therapy; LDL-C effect, не доказательство регрессии бляшки.
No news yet
CORALreef Outcomes
Phase 3NCT06008756
Cardiovascular-outcomes study, около 14 550 участников; enrollment завершён.
No news yet
OCEAN(a)-Outcomes
Phase 3NCT05581303
Randomized placebo-controlled, N≈7 297, established ASCVD + Lp(a) ≥200 nmol/L.
1 news item
ACCLAIM-CTA
Phase 3NCT07613294
Стартовал 02.06.2026: randomized double-blind placebo-controlled, N≈252, primary endpoint percent change in coronary noncalcified plaque volume.
No news yet
ACCLAIM-Lp(a)
Phase 3NCT06292013
~17 300 participants; outcome readout ориентировочно 2029.
1 news item
Lp(a)HORIZON (pelacarsen)
Phase 3NCT04023552
Randomized double-blind placebo-controlled, 8 323 участника с CVD и Lp(a) ≥70 mg/dL.
1 news item
STX-1150 (Tune/CasX epigenetic PCSK9 silencing), first-in-human
Phase 1NCT07428473
Open-label single-ascending-dose с expansion, план до 64 взрослых с повышенным LDL.
No news yet
Long-term follow-up of gene-editing recipients (up to 15 years)
NCT06112327
Отдельная long-term follow-up study: наблюдение получивших gene editing до 15 лет.
No news yet
VERVE-102 Heart-2
Phase 1NCT06164730
Open-label Phase 1, interim n=35, шесть single-dose cohorts 0.3–1.0 mg/kg; in vivo adenine base editing PCSK9.
1 news item
CTX310 Phase 1b (secondary identifier NCT07491172)
Phase 1NCT07491172
Secondary identifier к ACTRN12623000809639 (Phase 1b record).
No news yet
UDP-003 (Cyclarity), 7-ketocholesterol clearance
Early phase 1NCT06813339
Early Phase 1, 84 участника по плану; SAD/MAD у здоровых добровольцев и открытая когорта до 9 пациентов.
No news yet
PURIFY-TIMI 81 (YN001)
Phase 2NCT07521007
Phase 2b, N≈456, randomized double-blind placebo-controlled; primary endpoint relative change coronary noncalcified plaque volume.
1 news item
YN001 + evolocumab (Australia)
NCT06700720
N=24, без placebo/evolocumab-only arm; оба arm экспериментальные.
No news yet
YN001 liposomal rosuvastatin (Beijing Inno Medicine)
NCT06048588
Активно-таргетируемый липосомальный розувастатин; общая регистрация N=144, завершён. Предварительный анализ на ESC 2025 по 16 завершившим пациентам.
No news yet